The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Successful treatment of collagen‐induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity
Abstract
Objective: Extracellular high mobility group box chromosomal protein 1 (HMGB‐1) is a recently identified, endogenous, potent tumor necrosis factor– and interleukin‐1 (IL‐1)–inducing protein detectable in inflamed synovia in both human and experimental disease. In the present study, we examined clinical effects in collagen‐induced arthritis (CIA) using therapeutic administration of neutralizing HMGB‐1 antibodies or truncated HMGB‐1–derived A‐box protein, a specific, competitive antagonist of HMGB‐1. Methods: CIA was induced in DBA/1j mice or dark agouti rats, and animals were examined daily for signs of arthritis. Treatment with polyclonal anti–HMGB‐1 antibodies or the A‐box protein was initiated at the onset of disease and was administered intraperitoneally twice daily for 7 days. Animals were killed 8 days after initiation of therapy, and immunohistochemical analysis of synovial tissue specimens was performed. Results: Systemic administration of anti–HMGB‐1 antibodies or A‐box protein significantly reduced the mean arthritis score, the disease‐induced weight loss, and the histologic severity of arthritis. Beneficial effects were observed in both mice and rats. Immunohistochemical analysis revealed pronounced synovial IL‐1β expression and articular cartilage destruction in vehicle‐treated mice. Both these features were significantly less manifested in animals treated with anti–HMGB‐1 antibodies or A‐box protein. Conclusion: Counteracting extracellular HMGB‐1 with either neutralizing antibodies or a specific HMGB‐1 antagonist may offer a new method for the successful treatment of arthritis. Inflammation and tissue destruction were suppressed in CIA after HMGB‐1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
HMG-1 as a Late Mediator of Endotoxin Lethality in Mice
Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., et al. (1999) · Science · doi:10.1126/science.285.5425.248 · Cited by 3,385
Self-citationAndersson, U., Wang, H., Palmblad, K., Aveberger, A.-C., Bloom, O., Erlandsson-Harris, H., Janson, A., Kokkola, R., Zhang, M., Yang, H., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.565 · Cited by 1,401
Self-citationThe Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25752 · Cited by 1,151
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Williams, R. O., Feldmann, M., & Maini, R. N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.20.9784 · Cited by 989
Gardella, S., Andrei, C., Ferrera, D., Lotti, L. V., Torrisi, M. R., Bianchi, M. E., & Rubartelli, A. (2002) · EMBO reports · doi:10.1093/embo-reports/kvf198 · Cited by 926
Bustin, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5237 · Cited by 845
Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation
Abraham, E., Arcaroli, J., Carmody, A., Wang, H., & Tracey, K. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.2950 · Cited by 692
Self-citationThe biology of the receptor for advanced glycation end products and its ligands
Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(00)00087-2 · Cited by 691
Huttunen, H. J., Fages, C., & Rauvala, H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.28.19919 · Cited by 628
Cited by
DAMPs, PAMPs and alarmins: all we need to know about danger
Bianchi, M. E. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306164 · Cited by 2,794
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Lotze, M. T., & Tracey, K. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1594 · Cited by 2,487
Self-citationHMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
Self-citationHMGB1 and RAGE in Inflammation and Cancer
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436
Damage-associated molecular patterns in inflammatory diseases
Roh, J. S., & Sohn, D. H. (2018) · Immune Network · doi:10.4110/in.2018.18.e27 · Cited by 1,261
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2434651100 · Cited by 1,126
Self-citationThe Inflammatory Response to Cell Death
Rock, K. L., & Kono, H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151456 · Cited by 912
HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2
Yu, M., Wang, H., Ding, A., Golenbock, D. T., Latz, E., Czura, C. J., Fenton, M. J., Tracey, K. J., & Yang, H. (2006) · Shock · doi:10.1097/01.shk.0000225404.51320.82 · Cited by 832
Self-citationHMGB1: Endogenous Danger Signaling
Klune, J. R., Dhupar, R., Cardinal, J., Billiar, T. R., & Tsung, A. (2008) · Molecular Medicine · doi:10.2119/2008-00034.klune · Cited by 762
Midwood, K., Sacre, S., Piccinini, A. M., Inglis, J., Trebaul, A., Chan, E., Drexler, S., Sofat, N., Kashiwagi, M., Orend, G., et al. (2009) · Nature Medicine · doi:10.1038/nm.1987 · Cited by 703
HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease
Harris, H. E., Andersson, U., & Pisetsky, D. S. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.222 · Cited by 689
Self-citationSenescent cells as a source of inflammatory factors for tumor progression
Davalos, A. R., Coppe, J.-P., Campisi, J., & Desprez, P.-Y. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9220-9 · Cited by 636
Targeting Inflammation Driven by HMGB1
Yang, H., Wang, H., & Andersson, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00484 · Cited by 636
Self-citationThe cytokine activity of HMGB1
Yang, H., Wang, H., Czura, C. J., & Tracey, K. J. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1104648 · Cited by 545
Self-citationAlarmins: awaiting a clinical response
Chan, J. K., Roth, J., Oppenheim, J. J., Tracey, K. J., Vogl, T., Feldmann, M., Horwood, N., & Nanchahal, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62423 · Cited by 511
Self-citationMethotrexate an Old Drug with New Tricks
Bedoui, Y., Guillot, X., Sélambarom, J., Guiraud, P., Giry, C., Jaffar-Bandjee, M. C., Ralandison, S., & Gasque, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205023 · Cited by 471
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
Bertheloot, D., & Latz, E. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.34 · Cited by 455
Extracellular role of HMGB1 in inflammation and sepsis
Wang, H., Yang, H., & Tracey, K. J. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2003.01302.x · Cited by 439
Self-citationBianchi, M. E. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1008585 · Cited by 416
Mitroulis, I., Kambas, K., Chrysanthopoulou, A., Skendros, P., Apostolidou, E., Kourtzelis, I., Drosos, G. I., Boumpas, D. T., & Ritis, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029318 · Cited by 375
Mini‐review: The nuclear protein HMGB1 as a proinflammatory mediator
Erlandsson Harris, H., & Andersson, U. (2004) · European Journal of Immunology · doi:10.1002/eji.200424916 · Cited by 371
Self-citationMüller, S., Ronfani, L., & Bianchi, M. E. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2003.01296.x · Cited by 367
Liu, K., Mori, S., Takahashi, H. K., Tomono, Y., Wake, H., Kanke, T., Sato, Y., Hiraga, N., Adachi, N., Yoshino, T., et al. (2007) · The FASEB Journal · doi:10.1096/fj.07-8770com · Cited by 366
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
Curtin, J. F., Liu, N., Candolfi, M., Xiong, W., Assi, H., Yagiz, K., Edwards, M. R., Michelsen, K. S., Kroeger, K. M., Liu, C., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000010 · Cited by 364
The Role of HMGB1 in the Pathogenesis of Inflammatory and Autoimmune Diseases
Magna, M., & Pisetsky, D. S. (2014) · Molecular Medicine · doi:10.2119/molmed.2013.00164 · Cited by 358
High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule
Yang, H., Wang, H., Chavan, S. S., & Andersson, U. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00087 · Cited by 357
Self-citationMasquerader: High Mobility Group Box-1 and Cancer
Ellerman, J. E., Brown, C. K., de Vera, M., Zeh, H. J., Billiar, T., Rubartelli, A., & Lotze, M. T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1953 · Cited by 355
Mechanisms of Disease: a 'DAMP' view of inflammatory arthritis
Foell, D., Wittkowski, H., & Roth, J. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0531 · Cited by 352
Targeting HMGB1 in inflammation
Yang, H., & Tracey, K. J. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.11.019 · Cited by 351
Self-citationHigh-mobility group box 1 (HMGB1) protein: Friend and foe
ULLOA, L., & MESSMER, D. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.01.003 · Cited by 341
HMGB1: guiding immunity from within
Dumitriu, I. E., Baruah, P., Manfredi, A. A., Bianchi, M. E., & Rovere-Querini, P. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.04.009 · Cited by 340
An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
Musumeci, D., Roviello, G. N., & Montesarchio, D. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.001 · Cited by 334
High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells
Andersson, U., Yang, H., & Harris, H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.011 · Cited by 309
Self-citationHuman malarial disease: a consequence of inflammatory cytokine release
Clark, I. A., Budd, A. C., Alleva, L. M., & Cowden, W. B. (2006) · Malaria Journal · doi:10.1186/1475-2875-5-85 · Cited by 317
Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice
Stark, K., Philippi, V., Stockhausen, S., Busse, J., Antonelli, A., Miller, M., Schubert, I., Hoseinpour, P., Chandraratne, S., von Brühl, M.-L., et al. (2016) · Blood · doi:10.1182/blood-2016-04-710632 · Cited by 305
HMGB1 as a therapeutic target in disease
Xue, J., Suarez, J. S., Minaai, M., Li, S., Gaudino, G., Pass, H. I., Carbone, M., & Yang, H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30125 · Cited by 294
Self-citationHreggvidsdottir, H. S., Östberg, T., Wähämaa, H., Schierbeck, H., Aveberger, A.-C., Klevenvall, L., Palmblad, K., Ottosson, L., Andersson, U., & Harris, H. E. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0908548 · Cited by 290
Self-citationExtracellular HMGB1 as a therapeutic target in inflammatory diseases
Andersson, U., Yang, H., & Harris, H. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1439924 · Cited by 287
Self-citationRAGE: therapeutic target and biomarker of the inflammatory response—the evidence mounts
Ramasamy, R., Yan, S. F., & Schmidt, A. M. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0409230 · Cited by 283
Sterile inflammation and pregnancy complications: a review
Nadeau-Vallée, M., Obari, D., Palacios, J., Brien, M.-È., Duval, C., Chemtob, S., & Girard, S. (2016) · Reproduction · doi:10.1530/rep-16-0453 · Cited by 275
Emerging role of Toll-like receptors in atherosclerosis
Curtiss, L. K., & Tobias, P. S. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800056-jlr200 · Cited by 225
“By contrast, the A-box is anti-inflammatory and is therapeutically useful in models of endotoxemia, sepsis and arthritis (54, 55).”
High‐mobility group box‐1 in sterile inflammation
Tsung, A., Tohme, S., & Billiar, T. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12276 · Cited by 187
Neural regulators of innate immune responses and inflammation
Pavlov, V. A., & Tracey, K. J. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4102-3 · Cited by 174
Self-citationJiang, W., Bell, C. W., & Pisetsky, D. S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6495 · Cited by 134
HMGB1 is a bone‐active cytokine
Yang, J., Shah, R., Robling, A. G., Templeton, E., Yang, H., Tracey, K. J., & Bidwell, J. P. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21268 · Cited by 97
Self-citationTargeting HMGB1 TLR4 signaling as a novel approach to treatment of cerebral ischemia
Yang, Q.-W. (2010) · Frontiers in Bioscience · doi:10.2741/s119 · Cited by 55
Metadata
- Authors
- Kokkola, R., Li, J., Sundberg, E., Aveberger, A. ‐., Palmblad, K., Yang, H., Tracey, K. J., Andersson, U., & Harris, H. E.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-07
- Volume
- 48
- Issue
- 7
- Pages
- 2052-2058
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1970456030
- Cited by
- 325
- References
- 25
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.